Skip to main content
European Commission logo print header

A feasibility study on the development of Psorax35 as the first and only oral treatment for mild-to-moderate psoriasis with positive effects on co-morbidities.

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available